An estimated 3 million cases of C. difficile associated diarrhoea (CDAD) and colitis occur annually in the US, and the bacterium is believed to cause more deaths than traffic accidents in the UK. CDAD is a particularly serious illness, associated with the bacterium Clostridium difficile, and ranges from mild diarrhoea to life threatening conditions such as pseudomembranous colitis.
One of the main predisposing factors for the acquisition of CDAD is antibiotic therapy with broad spectrum antibiotics. When the normal bacteria living in the gut (the gut flora) are disturbed by antibiotics, C. difficile is able to proliferate and produce toxins that cause diarrhoea, lower abdominal pain and other symptoms such as nausea, fever and malaise. The problem is compounded by the fact that C. difficile forms spores which survive outside the body for long periods and are more resistant to chemical disinfectants. Patients with CDAD excrete large numbers of spores in their faeces; contaminating the hospital environment and spreading the disease.
Current treatments are largely confined to two potent antibiotics: metronidazole and vancomycin. However, treatment failures and relapses are common using these antibiotics. There is also a risk of spreading antibiotic resistance to other hospital pathogens.
The APC research team is investigating the potential of an antimicrobial peptide discovered in Cork as a novel therapeutic for the treatment of CDAD. Lacticin 3147 is produced by a harmless bacterium, Lactococcus lactis, one of a number of bacteria used by cheesemakers for millennia. When lacticin was tested against strains of C. difficile isolated from patients with diarrhoea or inflammatory bowel disease or healthy adults it was shown to be as effective as the antibiotics currently in use. This study, which is published in the current issue of Journal of Medical Microbiology, demonstrates that the potent antimicrobial lacticin can kill this dangerous pathogen at relatively low concentrations. Moreover, the team go on to show that lacticin is effective in killing the pathogen in contaminated faeces and suggest lacticin may be the basis for future therapies against the infection. The research is now focussing on optimising the delivery of lacticin to the colon and the potential for co-administration of lacticin-tolerant probiotics to restore a healthy gut flora.
Reference : Mary Rea et al., Journal Medical Microbiology (2007) 56, 940-946.
Catherine Buckley | alfa
Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania
The strange double life of Dab2
10.01.2017 | University of Miami Miller School of Medicine
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).
Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...
Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.
The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...
10.01.2017 | Event News
09.01.2017 | Event News
05.01.2017 | Event News
17.01.2017 | Earth Sciences
17.01.2017 | Materials Sciences
17.01.2017 | Architecture and Construction